Hans von Celsing

Mirada Medical Ltd. develops software applications for medical imaging. The firm's software allows images from multiple sources to be combined to provide greater clinical certainty in diagnosis and treatment of cancer. It provides radiology, radiation therapy, tumor board and referring physician solutions. The firm specializes in simplifying technically complex image quantification, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention. The company was founded by Mark E. Evans in 1999 and is headquartered in Oxford, the United Kingdom.

Bioxydyn Ltd. provides magnetic resonance imaging applications and services. Its services include imaging protocol and charter, on-site and remote training, quality management, and quantitative imaging biomarkers. The company was founded by Geoffrey James Martin Parker in 2009 and is headquartered in Manchester, the United Kingdom.

Established on 20th December 2007, ADAM SA was founded to promote scientific know-how and innovations in medical technology for cancer therapy. ADAM SA, headquartered in Geneva, Switzerland, aims to be a world's leading centre of excellence for research, engineering and industrialization of linear accelerators and detectors for medical applications. ADAM SA employs high-profile experts and specialists in physics and engineering and numbers important collaborations with hospitals, research centers and other world leading companies.

Plasma Surgical Ltd. specializes in groundbreaking pure-plasma technology for surgery. The private company is based in Abingdon, UK. The British company's flagship product, PlasmaJet Ultra+, is an all-in-one surgical tool that uses pure-plasma to cut, dissect, vaporize, coagulate, and surface seal tissue with control.

Partner Fondkommission AB provides financial advisory services. It offers mergers and acquisitions, brokerage, and issuer services. The company was founded in 2007 and is headquartered in Gothenburg, Sweden.

Gelmetix Ltd. offers a non-surgical procedure for the treatment of chronic lower back pain caused by degenerative disc disease. The firm develops a hydrogel to relieve back pain by enabling cells in the spinal disc to get back to normal functioning, which can be injected into the disc by a healthcare professional and replaces the need for invasive back surgery. The company was founded by Tony Freemont and Brian Saunders in 2012 and is headquartered in Cheshire, the United Kingdom.